Fig. 1

CAV2 was upregulated in OSCC and correlated with poor clinical outcomes. (A) Expression levels of CAV2 in OSCC (n=330) compared to normal samples (n=32) were analyzed using RNA sequencing data from TCGA. (B-C) Kaplan-Meier survival analysis of overall survival (B) and disease-specific survival (C) stratified by high and low CAV2 expression in OSCC patients. (D-I) CAV2 expression in OSCC of different clinical T stage, histologic grade, clinical N stage, clinical M stage, age, and gender. n=320, 322, 316, 313, 329, 330. (J and K) The cell types and their distribution in HNSC_GSE103322 datasets. (L) Distribution of CAV2 in different cells in HNSC_GSE103322 datasets. (M-O) CAV2 expression in OSCC and normal oral keratinocyte cell lines. mRNA levels were measured by RT-qPCR (M), protein levels by Western blot (N), and quantified in (O). (A, D-I) Data were overlaid by the median and IQR. (B-C) Data were presented as cumulative survival curves. (M-O) Data were represented as mean ± SD of three independent experiments. Significance was determined by the Wilcoxon rank sum test (A, H), the Logrank test (B-C), the Kruskal-Wallis test with Dunn’s multiple comparison tests (D, E), Welch t’ test (I), Welch one-way ANOVA test with a post-hoc Games-Howell (F), one-way ANOVA (M and O). *P < 0.05, **P < 0.01, ***P < 0.001, ns: no significance. CAV2: C aveolin2; OSCC: oral squamous cell carcinoma; TCGA: T he Cancer Genome Atlas; RT-qPCR: real-time quantitative polymerase chain reaction; IQR: interquartile range